Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Clp (ADMET) | = 134 ml min-1 kg-1 | Pharmacokinetic parameter clearance of the compound in dog was reported in Cassette dosage | ChEMBL. | 12190311 |
Clp (ADMET) | = 197 ml min-1 kg-1 | Pharmacokinetic parameter clearance of the compound in dog was reported in Discrete dosage | ChEMBL. | 12190311 |
T1/2 (ADMET) | = 0.2 hr | Half life time of the compound in dog was reported in Discrete dosage | ChEMBL. | 12190311 |
T1/2 (ADMET) | = 0.7 hr | Half life time of the compound in dog was reported in casette dosage | ChEMBL. | 12190311 |
Varea (ADMET) | = 3.5 l kg-1 | Pharmacokinetic parameter Varea of the compound in dog was reported in Discrete dosage | ChEMBL. | 12190311 |
Varea (ADMET) | = 7.6 l kg-1 | Pharmacokinetic parameter Varea of the compound in dog was reported in Cassette dosage | ChEMBL. | 12190311 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.